FDA.GOV: FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations On October 26, 2026, the U.S. Food and Drug Administration (FDA) approved talazoparib (Talzenna) in combination with enzalutamide for certain patients with metastatic prostate cancer who have specific genetic mutations. The approval follows clinical trial results showing the treatment combination significantly delayed cancer progression, offering an additional treatment option for eligible patients.Read the full article here. About Prostate Cancer Prostate Cancer News More for you
On October 26, 2026, the U.S. Food and Drug Administration (FDA) approved talazoparib (Talzenna) in combination with enzalutamide for certain patients with metastatic prostate cancer who have specific genetic mutations. The approval follows clinical trial results showing the treatment combination significantly delayed cancer progression, offering an additional treatment option for eligible patients.Read the full article here.
